Catalyst Pharmaceuticals Upgraded to Strong Buy as EPS Estimates Climb 2%
Catalyst Pharmaceuticals has been upgraded to a Zacks Rank #1 (Strong Buy) and featured among top value stock picks on March 4. EPS estimates for 2026 rose from $2.54 to $2.59 over the past 60 days while shares climbed 9.2% year-over-year and 2.5% year-to-date.
1. Zacks Rank Upgrade
Catalyst Pharmaceuticals earned a Zacks Rank #1 (Strong Buy) rating, reflecting increased analyst confidence in the company’s earnings trajectory and potential upside from its lead therapies.
2. EPS Estimate Revisions
Analysts have raised 2026 EPS forecasts from $2.54 to $2.59 over the past 60 days, driven by stronger-than-expected prescription growth and favorable clinical data updates.
3. Stock Performance and Value Listing
Shares have gained 9.2% over the past 12 months and 2.5% year-to-date, and Catalyst was highlighted among top value stocks on March 4, underscoring growing investor interest.